{"gene":"PDE3A","run_date":"2026-04-29T11:37:58","timeline":{"discoveries":[{"year":2002,"finding":"Three PDE3A isoforms (PDE3A-136, PDE3A-118, PDE3A-94) exist in cardiac myocytes, translated from two mRNAs derived from the PDE3A1 gene; they differ in N-terminal sequences containing membrane-association domains and phosphorylation/activation sites for PKA and PKB, determining their distinct subcellular localizations.","method":"Western blotting with isoform-specific antibodies, in vitro transcription/translation, RT-PCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, replicated within a single rigorous study","pmids":["12154085"],"is_preprint":false},{"year":2006,"finding":"PKB/Akt phosphorylates PDE3A at serines 290-292 in mouse oocytes, increasing cAMP-hydrolytic activity and promoting meiotic maturation; mutation of these serines to alanine greatly diminishes insulin-dependent maturation in Xenopus and mouse oocytes.","method":"Cell-free kinase assay with recombinant PDE3A and PKB/Akt, site-directed mutagenesis, microinjection of myr-Akt into oocytes, pde3a(-/-) rescue experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro phosphorylation, mutagenesis, and functional rescue in two model organisms","pmids":["17124499"],"is_preprint":false},{"year":2015,"finding":"Phosphorylation of human PDE3A1 by PKA at Ser-292/Ser-293 (unique to PDE3A1 N-terminal extension) promotes incorporation of PDE3A1 into a SERCA2/AKAP18 signalosome in the sarcoplasmic reticulum, where it regulates PLB phosphorylation and SERCA2 activity controlling cardiac contractility.","method":"Co-immunoprecipitation, gel filtration chromatography, recombinant protein phosphorylation assay, N-terminal deletion mutants, Ser-to-Ala substitution mutagenesis, immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis, reconstitution with recombinant proteins, and co-IP in human SR fractions","pmids":["25593322"],"is_preprint":false},{"year":2015,"finding":"Gain-of-function missense mutations in PDE3A increase PKA-mediated phosphorylation of PDE3A, resulting in increased cAMP-hydrolytic activity, enhanced VSMC and chondrocyte proliferation, diminished phospho-VASP levels, and dysregulated PTHrP, causing autosomal dominant hypertension with brachydactyly.","method":"In vitro cAMP hydrolysis assays on MSC-derived VSMCs and chondrocytes, analysis of phosphorylation state, VASP and PTHrP measurements","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — functional in vitro assays on disease-relevant cells with multiple molecular readouts","pmids":["25961942"],"is_preprint":false},{"year":2015,"finding":"DNMDP binding to PDE3A promotes a neomorphic protein-protein interaction between PDE3A and Schlafen 12 (SLFN12), and coexpression of both proteins is required for DNMDP-induced cancer cell death; PDE3A depletion confers DNMDP resistance.","method":"Phenotypic compound library screening across 766 cancer cell lines, target deconvolution by predictive chemogenomics, co-immunoprecipitation, siRNA knockdown","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, genetic depletion with defined phenotypic readout, large-scale correlative validation","pmids":["26656089"],"is_preprint":false},{"year":2021,"finding":"PDE3A and SLFN12 form a heterotetramer stabilized by DNMDP; interactions between the C-terminal alpha helix of SLFN12 and residues near the PDE3A active site are required for complex formation; PDE3A binding increases SLFN12 RNase activity, and SLFN12 RNase activity is required for DNMDP-induced cell death.","method":"Crystal/cryo-EM structure of PDE3A-SLFN12 complex, mutagenesis of interface residues, in vitro RNase activity assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — structural determination with mutagenesis and functional validation of enzymatic activity","pmids":["34272366"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structures of PDE3A-SLFN12 heterotetramer bound to anagrelide, nauclefine, or DNMDP reveal that molecular glue compounds bind the PDE3A catalytic domain pocket and create a modified interface that recruits the SLFN12 short helix (E552-I558) via hydrophobic interactions; SLFN12 activation blocks protein translation leading to apoptosis.","method":"High-resolution cryo-EM of complexes isolated from drug-treated HeLa cells, structure-based analog design","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — independent cryo-EM structure corroborating and extending the companion structural study","pmids":["34707099"],"is_preprint":false},{"year":2009,"finding":"Platelet agonists (e.g., thrombin via PAR-1) activate PKC to phosphorylate PDE3A on Ser-312, Ser-428, Ser-438, Ser-465, and Ser-492, increasing cAMP hydrolysis and promoting association of PDE3A with 14-3-3 proteins; PKC activation, but not PI3K/PKB, mTOR/p70S6K, or ERK/RSK, is required for this phosphorylation.","method":"Mass spectrometry phosphosite identification, pharmacological inhibition of kinase pathways, co-immunoprecipitation with 14-3-3","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — MS-identified phosphosites combined with selective kinase inhibitors and reciprocal co-IP","pmids":["19261611"],"is_preprint":false},{"year":2002,"finding":"In gastric smooth muscle, PKA phosphorylates PDE3A (not PDE3B) and activates its cAMP-hydrolytic activity; cGMP inhibits PDE3 activity and augments cAMP levels; PKG does not regulate PDE3A phosphorylation.","method":"RT-PCR/Western blot for isoform identification, PKA/PKG-selective pharmacological tools (PKI, H-89, KT-5823), PDE activity assays, phosphorylation assays","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple selective inhibitors used orthogonally with enzymatic activity assays","pmids":["11832336"],"is_preprint":false},{"year":2011,"finding":"PDE3A deletion in VSMCs suppresses mitogen-induced proliferation via two complementary pathways: (1) elevated PKA activity causes inhibitory phosphorylation of Raf-1 (Ser-259), reducing ERK activation; (2) PKA/CREB-mediated induction of p21 and p53 accumulation elevates MKP-1 and causes G0/G1 cell cycle arrest.","method":"PDE3A knockout mouse VSMCs, adenoviral CREB overexpression, siRNA knockdown of p53, ERK/Raf-1 phosphorylation assays, cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple pathway readouts, genetic rescue experiments","pmids":["21632535"],"is_preprint":false},{"year":2013,"finding":"PDE3A1 and PDE3A2 isoforms are phosphorylated at different sites by distinct kinases in cardiac myocytes: isoproterenol/PKA selectively phosphorylates PDE3A1 at S312 (14-3-3 binding site), while PMA/PKC selectively phosphorylates PDE3A2 at S428; phosphorylation at S428 stimulates PDE3A2 activity but S312 phosphorylation does not affect PDE3A1 activity; the two isoforms have distinct protein interactomes.","method":"FLAG-tagged isoform expression in HEK293 cells, phospho-specific detection, gel filtration chromatography, 2D electrophoresis of co-immunoprecipitated proteins, human myocardium validation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, validated in human myocardium","pmids":["24248367"],"is_preprint":false},{"year":2010,"finding":"PDE3A physically and functionally interacts with CFTR at the plasma membrane; PDE3A inhibition generates compartmentalized cAMP that further clusters PDE3A and CFTR into microdomains; actin cytoskeleton disruption reduces PDE3A-CFTR interaction and abolishes compartmentalized cAMP signaling and CFTR channel potentiation.","method":"Co-immunoprecipitation, pharmacological PDE3A inhibition, actin disruption, CFTR channel electrophysiology, gland secretion assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, functional channel assay, physiological tissue model","pmids":["20089840"],"is_preprint":false},{"year":2000,"finding":"Conserved histidine and glutamate residues in the two HXXXH(X)25E metal-binding motifs of PDE3A are critical for catalysis and substrate/inhibitor binding: H752, H756, E825 mutations abolish or greatly reduce catalytic activity; H836A increases Ki for cGMP 177-fold; E866A increases Km for cAMP 11-fold and Ki for cGMP 27-fold; E971A increases Km 5-fold.","method":"Site-directed mutagenesis, expression in baculovirus/Sf9 system, kinetic analysis (kcat, Km, Ki)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinetic analysis of multiple active-site mutants with rigorous controls","pmids":["10828019"],"is_preprint":false},{"year":1998,"finding":"Site-directed mutagenesis of platelet PDE3A identified H840 as essential for catalysis (likely coordinates Mn2+) and H869 as important for cGMP inhibitor binding (H869A increases Km for cAMP and IC50 for cGMP fourfold each); C816 in the 44-aa PDE3-unique insert is essential for proper folding.","method":"Site-directed mutagenesis, expression in PDE-deficient yeast Saccharomyces cerevisiae, kinetic analysis","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinetic characterization of multiple mutants","pmids":["9826434"],"is_preprint":false},{"year":1996,"finding":"The PDE3A catalytic domain is localized to amino acid residues 679-1141; deletion constructs PDE3Adelta1 (aa 665-1141) and PDE3Adelta2 (aa 679-1141) retain catalytic activity, while PDE3Adelta3 (aa 686-1141) and PDE3Adelta4 (aa 700-1141) do not.","method":"Deletion mutagenesis, expression in PDE-deficient yeast, PDE activity assays, Western blotting","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — systematic deletion analysis with activity measurements","pmids":["8695850"],"is_preprint":false},{"year":2001,"finding":"Mouse oocyte PDE3A is recovered predominantly in the soluble fraction when N-terminally truncated (Delta346aa or Delta608aa), whereas full-length recombinant PDE3A is in the particulate fraction; the N-terminal region contains the membrane-association determinants.","method":"Subcellular fractionation of Leydig cell-expressed truncation mutants, pharmacological profiling vs. oocyte PDE activity","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 — direct fractionation of defined deletion mutants, correlated with functional inhibitor profiling","pmids":["11420239"],"is_preprint":false},{"year":2001,"finding":"A vascular smooth muscle cell PDE3A isoform (PDE3A2/~118 kDa) is generated from the same gene as cardiac PDE3A1 via a pre-translational mechanism that removes the first 145 N-terminal amino acids of PDE3A1, including one membrane-association domain.","method":"cDNA cloning from aortic myocytes, 5'-RACE, RT-PCR, ribonuclease protection assay, Western blotting with region-specific antibodies, Sf9 expression","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — multiple molecular biology methods converging on same conclusion","pmids":["11115397"],"is_preprint":false},{"year":2010,"finding":"In PDE3A(-/-) oocytes, elevated PKA activity inactivates both Cdc2 and Plk1, inhibits histone H3-S10 phosphorylation and Cdc25B dephosphorylation, causing G2/M arrest; PKAc fails to translocate to the nucleus; Plk1 is reactivated by PKA inhibitor; PDE3A co-immunoprecipitates with Plk1 and PKAc can phosphorylate and inhibit Plk1 in vitro.","method":"PDE3A knockout mouse oocytes, in vitro PKA phosphorylation of recombinant Plk1, co-immunoprecipitation, PKA inhibitor (Rp-cAMPS) rescue, subcellular localization imaging","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 — genetic KO, in vitro kinase assay, co-IP, and pharmacological rescue","pmids":["21099356"],"is_preprint":false},{"year":1998,"finding":"In rat tissues and VSMCs, PDE3A is expressed as a ~120 kDa protein found exclusively in the cytosolic fraction, whereas PDE3B (~135 kDa) is found only in the particulate fraction; prolonged elevation of cAMP increases PDE3A and PDE3B expression and shifts PDE3 activity to particulate fractions.","method":"Subcellular fractionation, immunoblotting with isoform-selective antisera, RT-PCR, cAMP-elevating agent treatment","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 — direct fractionation with isoform-specific detection across multiple tissues","pmids":["9884079"],"is_preprint":false},{"year":2015,"finding":"Chemical proteomics using an IBMX-based affinity resin in HeLa cells identified the PDE3A interactome, including 14-3-3 proteins and a PP2A complex (regulatory, scaffold, and catalytic subunits) as endogenous PDE3A-associated proteins.","method":"Chemical proteomics (IBMX-affinity resin + selective competitor PDE inhibitors), mass spectrometry identification of co-purified proteins","journal":"Molecular bioSystems","confidence":"Medium","confidence_rationale":"Tier 2 — MS-based interactome with competitive specificity controls, single lab","pmids":["26205238"],"is_preprint":false},{"year":2016,"finding":"PDE3A hydrolyzes cUMP with low affinity (Km ~143 μM) and high velocity (Vmax ~42 μmol/min/mg), compared to cAMP (Km ~0.7 μM, Vmax ~1.2 μmol/min/mg); the PDE3 inhibitor milrinone inhibits cUMP hydrolysis by PDE3A with Ki = 57 nM.","method":"In vitro enzyme kinetics with HPLC-MS/MS detection of UMP and AMP products, milrinone inhibition assay","journal":"Naunyn-Schmiedeberg's archives of pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 — rigorous in vitro kinetic characterization, single study","pmids":["27975297"],"is_preprint":false},{"year":2022,"finding":"Cytotoxic PDE3A modulators act as molecular glues inducing PDE3A-SLFN12 association; the PDE3A-SLFN12 interaction stabilizes cytoplasmic SLFN12 and induces SLFN12 dephosphorylation at Ser-368 and Ser-573; this dephosphorylation is required for cell death and promotes rRNA RNase activity of SLFN12.","method":"Co-immunoprecipitation, mutational analysis of SLFN12 phosphosites, RNase activity assay, cell viability with phospho-mimetic/alanine mutants","journal":"Cell chemical biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP plus mutagenesis of phosphosites with functional cell-death readout, multiple orthogonal methods","pmids":["35104454"],"is_preprint":false},{"year":2019,"finding":"ATF3 transcription factor binds a 29-nt insertion polymorphism in the PDE3A promoter and represses cAMP-dependent PDE3A1 transcription; a nearby cAMP response element enhancer is blocked by the insertion, explaining differential PDE3A1 expression in response to PDE3 inhibitor treatment in heart failure patients.","method":"Luciferase reporter assay, mRNA RT-PCR in explanted human LV, PDE enzyme activity assay, promoter deletion analysis","journal":"Journal of the American College of Cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional promoter assay and human tissue validation, single lab","pmids":["30871701"],"is_preprint":false},{"year":2017,"finding":"SFPQ (splicing factor proline and glutamine rich) binds upstream regulatory regions of PDE3A and activates its transcription; serum-induced PDE3A expression is dependent on SFPQ binding; PDE3A transcription initiates from multiple start sites within exon 1.","method":"5'-RACE for transcription start site mapping, ChIP-seq for SFPQ binding sites, SFPQ overexpression and knockdown effects on PDE3A mRNA","journal":"Bioscience reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq plus functional expression analysis, single lab","pmids":["28743736"],"is_preprint":false},{"year":2020,"finding":"In human pulmonary artery smooth muscle cells, nitric oxide increases PDE3A protein expression and PDE3 activity via the sGC-cGMP pathway, leading to decreased cAMP and increased AMPK phosphorylation; siRNA knockdown of PDE3A blunts NO-induced AMPK activation.","method":"siRNA knockdown, Western blotting, cAMP assay, pharmacological sGC stimulator/inhibitor","journal":"Physiological reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown with specific mechanistic pathway readout, single lab","pmids":["32914566"],"is_preprint":false},{"year":2019,"finding":"miR-27a-3p and miR-222-3p directly reduce PDE3A protein expression in human cerebral microvascular endothelial cells (hCMEC/D3) when transfected as mimics.","method":"miRNA mimic transfection, Western blotting","journal":"Molecular neurobiology","confidence":"Low","confidence_rationale":"Tier 3 — single method (Western blot after miRNA transfection), single lab, no functional consequence established","pmids":["30603956"],"is_preprint":false},{"year":1992,"finding":"The cGMP-inhibited PDE (PDE3A) in 3T3-L1 adipocyte particulate fractions is phosphorylated in response to beta-agonist or insulin in intact cells, indicating hormonal regulation of PDE3A phosphorylation state.","method":"32P metabolic labeling, immunoprecipitation with anti-cGI PDE antibody","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct in-cell phosphorylation assay with two distinct hormonal stimuli, foundational early study","pmids":["1314573"],"is_preprint":false}],"current_model":"PDE3A is a cAMP/cGMP-hydrolyzing phosphodiesterase whose activity is regulated by PKA, PKC, and PKB/Akt-mediated phosphorylation at distinct isoform-specific sites; in the heart, PKA phosphorylation of PDE3A1 at Ser-292/293 drives its assembly into SERCA2/AKAP18 signalosomes that control contractility, while in oocytes PKB/Akt phosphorylation at Ser-290-292 activates PDE3A to lower cAMP and trigger meiotic resumption; in platelets and VSMCs, PKC phosphorylation activates PDE3A and promotes 14-3-3 binding, suppressing cAMP signaling; gain-of-function mutations in PDE3A hyperactivate the enzyme causing familial hypertension with brachydactyly; and independently of its enzymatic function, certain small-molecule 'velcrin' modulators induce PDE3A to form a heterotetramer with SLFN12, activating SLFN12's tRNase activity and inducing cancer cell apoptosis."},"narrative":{"teleology":[{"year":1992,"claim":"Establishing that PDE3A is hormonally regulated by phosphorylation set the stage for understanding how catecholamines and insulin tune cAMP hydrolysis in intact cells.","evidence":"32P metabolic labeling and immunoprecipitation in 3T3-L1 adipocytes after beta-agonist or insulin stimulation","pmids":["1314573"],"confidence":"Medium","gaps":["Kinase identity not determined","Phosphorylation sites not mapped","Functional consequence on PDE activity not directly measured"]},{"year":1996,"claim":"Defining the catalytic domain boundaries (residues 679–1141) and identifying essential metal-coordinating histidine/glutamate residues resolved how PDE3A achieves dual cAMP/cGMP hydrolysis and how cGMP acts as a competitive inhibitor.","evidence":"Systematic deletion mutagenesis in PDE-deficient yeast and site-directed mutagenesis with kinetic analysis of recombinant enzyme","pmids":["8695850","9826434","10828019"],"confidence":"High","gaps":["No crystal structure of PDE3A catalytic domain alone at this stage","Precise mechanism of cGMP competitive inhibition at atomic resolution unresolved"]},{"year":2001,"claim":"Discovery that the PDE3A N-terminal region encodes membrane-association determinants and that alternative pre-translational mechanisms generate tissue-specific isoforms (PDE3A1 vs PDE3A2) explained how a single gene produces proteins with distinct subcellular distributions in heart versus vasculature.","evidence":"Subcellular fractionation of N-terminal truncation mutants, 5'-RACE, and isoform-specific antibodies across rat tissues and VSMCs","pmids":["11420239","11115397","9884079"],"confidence":"High","gaps":["Mechanism of alternative translation initiation not fully characterized","Functional non-redundancy of isoforms not yet demonstrated"]},{"year":2002,"claim":"Identification of three cardiac PDE3A isoforms (PDE3A1/136, PDE3A2/118, PDE3A3/94 kDa) from two mRNAs, each with unique N-terminal PKA/PKB sites, established the molecular basis for isoform-specific regulation in the heart.","evidence":"Isoform-specific antibodies, in vitro transcription/translation, RT-PCR in cardiac myocytes","pmids":["12154085"],"confidence":"High","gaps":["In vivo functional distinction between isoforms in intact heart not yet shown"]},{"year":2006,"claim":"Demonstrating that PKB/Akt phosphorylates PDE3A at Ser-290–292 to activate cAMP hydrolysis and trigger meiotic resumption revealed PDE3A as the critical effector downstream of insulin/PI3K signaling in oocyte maturation.","evidence":"Cell-free kinase assay, Ser-to-Ala mutagenesis, microinjection of myr-Akt, pde3a−/− oocyte rescue in Xenopus and mouse","pmids":["17124499"],"confidence":"High","gaps":["Whether additional kinases co-regulate PDE3A in oocytes not excluded","Structural basis of phosphorylation-induced activation unknown"]},{"year":2009,"claim":"Mapping five PKC-dependent phosphorylation sites (Ser-312, -428, -438, -465, -492) on platelet PDE3A and showing that these drive 14-3-3 binding revealed a distinct kinase-specific regulatory module controlling cAMP in hemostasis.","evidence":"Mass spectrometry phosphosite identification, selective kinase inhibitors, co-IP with 14-3-3 in thrombin-stimulated platelets","pmids":["19261611"],"confidence":"High","gaps":["Functional consequence of individual phosphosites on platelet aggregation not dissected","Identity of specific 14-3-3 isoforms involved not defined"]},{"year":2010,"claim":"Showing that PDE3A−/− oocytes arrest at G2/M because elevated PKA inactivates Plk1 and Cdc2, and that PDE3A co-immunoprecipitates with Plk1, positioned PDE3A within the meiotic cell-cycle kinase cascade.","evidence":"PDE3A knockout mouse oocytes, in vitro PKA phosphorylation of Plk1, co-IP, PKA inhibitor rescue","pmids":["21099356"],"confidence":"High","gaps":["Direct PKA phosphosite on Plk1 that mediates inhibition not mapped in vivo","Whether PDE3A-Plk1 interaction is direct or scaffold-mediated unknown"]},{"year":2010,"claim":"Demonstration that PDE3A interacts with CFTR at the plasma membrane and that actin cytoskeleton integrity is required for this compartmentalized cAMP signaling revealed PDE3A as a regulator of chloride channel function.","evidence":"Reciprocal co-IP, CFTR electrophysiology, actin disruption in airway epithelial cells","pmids":["20089840"],"confidence":"High","gaps":["Whether PDE3A directly binds CFTR or via an adaptor not resolved","Physiological impact on mucociliary clearance not tested in vivo"]},{"year":2011,"claim":"PDE3A deletion in VSMCs established that PDE3A sustains proliferative signaling through two parallel cAMP-PKA-suppressive arms: enabling Raf-1/ERK activation and preventing p21/p53-mediated G0/G1 arrest.","evidence":"PDE3A knockout mouse VSMCs, adenoviral CREB overexpression, p53 siRNA rescue, ERK/Raf-1 phosphorylation assays","pmids":["21632535"],"confidence":"High","gaps":["Contribution of PDE3A versus PDE3B to in vivo vascular remodeling not separated","Relevance to human atherosclerotic VSMCs not confirmed"]},{"year":2013,"claim":"Revealing that PKA selectively phosphorylates PDE3A1 at Ser-312 (promoting 14-3-3 binding without increasing activity) while PKC selectively phosphorylates PDE3A2 at Ser-428 (stimulating activity) demonstrated isoform-specific regulatory logic within the same cell type.","evidence":"FLAG-tagged isoform expression in HEK293, phospho-specific detection, gel filtration, validated in human myocardium","pmids":["24248367"],"confidence":"High","gaps":["Distinct interactomes of PDE3A1 vs PDE3A2 identified by 2D-gel but individual partners not validated","Functional cardiac phenotype of isoform-selective disruption not tested"]},{"year":2015,"claim":"PKA phosphorylation of PDE3A1 at Ser-292/293 was shown to drive its incorporation into a SERCA2/AKAP18 signalosome at the sarcoplasmic reticulum, directly linking PDE3A1 to regulation of PLB phosphorylation and cardiac contractility.","evidence":"Co-IP, gel filtration, Ser-to-Ala mutagenesis, recombinant protein reconstitution in human SR fractions","pmids":["25593322"],"confidence":"High","gaps":["In vivo cardiac functional consequence of disrupting PDE3A1-AKAP18 interaction not demonstrated","Stoichiometry of the signalosome not determined"]},{"year":2015,"claim":"Identification of gain-of-function PDE3A mutations as the cause of autosomal dominant hypertension with brachydactyly type E established PDE3A as a disease gene and connected enhanced cAMP hydrolysis to vascular and skeletal pathology.","evidence":"In vitro cAMP hydrolysis assays on MSC-derived VSMCs/chondrocytes from mutation carriers, phospho-VASP and PTHrP measurements","pmids":["25961942"],"confidence":"High","gaps":["Precise structural mechanism by which mutations enhance phosphorylation-dependent activation not resolved","Contribution of vascular versus skeletal phenotype to hypertension not dissected"]},{"year":2015,"claim":"Discovery that small-molecule DNMDP induces a neomorphic PDE3A–SLFN12 protein-protein interaction essential for selective cancer cell killing opened a catalysis-independent, molecular-glue function for PDE3A.","evidence":"Chemogenomic screening across 766 cancer cell lines, co-IP, siRNA resistance studies","pmids":["26656089"],"confidence":"High","gaps":["Mechanism of cell death downstream of PDE3A-SLFN12 complex not yet defined","Structural basis of glue-induced interaction unknown at this point"]},{"year":2021,"claim":"Cryo-EM and crystal structures of the PDE3A–SLFN12 heterotetramer revealed that molecular glues bind the PDE3A catalytic pocket and create a hydrophobic interface that recruits a SLFN12 C-terminal helix, activating SLFN12 RNase activity to block translation and induce apoptosis.","evidence":"Cryo-EM structures with DNMDP/anagrelide/nauclefine, mutagenesis of interface residues, in vitro RNase assay","pmids":["34272366","34707099"],"confidence":"High","gaps":["In vivo tRNA substrate specificity of activated SLFN12 not fully characterized","Determinants of cancer-cell selectivity beyond PDE3A-SLFN12 coexpression not defined"]},{"year":2022,"claim":"Showing that PDE3A-SLFN12 complex formation triggers SLFN12 dephosphorylation at Ser-368/Ser-573 and that this dephosphorylation is required for rRNA cleavage and cell death added a phosphorylation-dependent gating step to the molecular-glue killing mechanism.","evidence":"Co-IP, phosphosite-mimetic/alanine mutagenesis of SLFN12, RNase activity assay, cell viability readouts","pmids":["35104454"],"confidence":"High","gaps":["Phosphatase responsible for SLFN12 dephosphorylation not identified","Whether other Schlafen family members can substitute for SLFN12 not tested"]},{"year":null,"claim":"Major open questions include: the structural basis of phosphorylation-induced PDE3A activation, the atomic-resolution structure of PDE3A catalytic domain alone, the in vivo cardiac phenotype of isoform-selective PDE3A disruption, the phosphatase acting on SLFN12 in the molecular-glue pathway, and the determinants beyond coexpression that confer cancer-cell selectivity to velcrin compounds.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of PDE3A catalytic domain alone","In vivo isoform-selective genetic models lacking","Phosphatase for SLFN12 dephosphorylation unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[12,13,14,20]},{"term_id":"GO:0009975","term_label":"cyclase activity","supporting_discovery_ids":[12,13,20]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15,18]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[11,15,18]},{"term_id":"GO:0043226","term_label":"organelle","supporting_discovery_ids":[2,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,7,8,9,11]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,9,17]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[2]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,5,6,21]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[1,17]}],"complexes":["SERCA2/AKAP18/PDE3A1 signalosome","PDE3A-SLFN12 heterotetramer"],"partners":["SLFN12","AKAP18","ATP2A2","PLN","CFTR","YWHAZ","PLK1","PPP2CA"],"other_free_text":[]},"mechanistic_narrative":"PDE3A is a dual-specificity cyclic nucleotide phosphodiesterase that hydrolyzes cAMP and cGMP, with cGMP also acting as a competitive inhibitor, and serves as a critical regulator of cAMP compartmentalization in cardiovascular, reproductive, and hematopoietic cells [PMID:10828019, PMID:8695850]. Three N-terminal isoforms (PDE3A1/136 kDa, PDE3A2/118 kDa, PDE3A3/94 kDa), generated by alternative translation initiation from a single gene, differ in membrane-association domains and phosphorylation sites, conferring distinct subcellular localizations and signalosome partnerships: PKA phosphorylation of PDE3A1 at Ser-292/293 drives its assembly into a SERCA2/AKAP18 complex at the sarcoplasmic reticulum to control cardiac contractility, PKB/Akt phosphorylation at Ser-290–292 activates PDE3A in oocytes to lower cAMP and permit meiotic resumption, and PKC phosphorylation in platelets promotes 14-3-3 binding and cAMP suppression [PMID:12154085, PMID:25593322, PMID:17124499, PMID:19261611]. In vascular smooth muscle cells, PDE3A deletion elevates PKA activity, which inhibits Raf-1/ERK signaling and induces p21/p53-dependent G0/G1 arrest, suppressing proliferation [PMID:21632535]. Gain-of-function PDE3A mutations cause autosomal dominant hypertension with brachydactyly type E, and independently of catalytic activity, small-molecule molecular glues induce PDE3A to form a heterotetramer with SLFN12, activating SLFN12 RNase/translational shutdown and triggering cancer cell apoptosis [PMID:25961942, PMID:34272366, PMID:34707099]."},"prefetch_data":{"uniprot":{"accession":"Q14432","full_name":"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A","aliases":["Cyclic GMP-inhibited phosphodiesterase A","CGI-PDE A","cGMP-inhibited cAMP phosphodiesterase","cGI-PDE"],"length_aa":1141,"mass_kda":125.0,"function":"Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (PubMed:1315035, PubMed:25961942, PubMed:8155697, PubMed:8695850). Also has activity toward cUMP (PubMed:27975297). Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling (PubMed:31420216, PubMed:34707099)","subcellular_location":"Membrane; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/Q14432/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE3A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE3A","total_profiled":1310},"omim":[{"mim_id":"608742","title":"HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 4","url":"https://www.omim.org/entry/608742"},{"mim_id":"602047","title":"PHOSPHODIESTERASE 3B; PDE3B","url":"https://www.omim.org/entry/602047"},{"mim_id":"171890","title":"PHOSPHODIESTERASE 1A; PDE1A","url":"https://www.omim.org/entry/171890"},{"mim_id":"123805","title":"PHOSPHODIESTERASE 3A; PDE3A","url":"https://www.omim.org/entry/123805"},{"mim_id":"112410","title":"HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB","url":"https://www.omim.org/entry/112410"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":19.9},{"tissue":"heart muscle","ntpm":28.0}],"url":"https://www.proteinatlas.org/search/PDE3A"},"hgnc":{"alias_symbol":["CGI-PDE"],"prev_symbol":[]},"alphafold":{"accession":"Q14432","domains":[{"cath_id":"-","chopping":"133-179_193-259","consensus_level":"high","plddt":72.1366,"start":133,"end":259},{"cath_id":"1.10.1300.10","chopping":"683-780_800-957","consensus_level":"high","plddt":94.6516,"start":683,"end":957}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14432","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14432-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14432-F1-predicted_aligned_error_v6.png","plddt_mean":60.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE3A","jax_strain_url":"https://www.jax.org/strain/search?query=PDE3A"},"sequence":{"accession":"Q14432","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14432.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14432/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14432"}},"corpus_meta":[{"pmid":"25961942","id":"PMC_25961942","title":"PDE3A mutations cause autosomal dominant hypertension with brachydactyly.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25961942","citation_count":127,"is_preprint":false},{"pmid":"12154085","id":"PMC_12154085","title":"Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12154085","citation_count":107,"is_preprint":false},{"pmid":"17124499","id":"PMC_17124499","title":"Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17124499","citation_count":101,"is_preprint":false},{"pmid":"9884079","id":"PMC_9884079","title":"Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.","date":"1998","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9884079","citation_count":96,"is_preprint":false},{"pmid":"25593322","id":"PMC_25593322","title":"Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25593322","citation_count":83,"is_preprint":false},{"pmid":"26656089","id":"PMC_26656089","title":"Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.","date":"2015","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26656089","citation_count":81,"is_preprint":false},{"pmid":"19261611","id":"PMC_19261611","title":"Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19261611","citation_count":79,"is_preprint":false},{"pmid":"25877153","id":"PMC_25877153","title":"Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25877153","citation_count":73,"is_preprint":false},{"pmid":"34272366","id":"PMC_34272366","title":"Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34272366","citation_count":70,"is_preprint":false},{"pmid":"11832336","id":"PMC_11832336","title":"PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.","date":"2002","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11832336","citation_count":69,"is_preprint":false},{"pmid":"21632535","id":"PMC_21632535","title":"Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21632535","citation_count":65,"is_preprint":false},{"pmid":"20089840","id":"PMC_20089840","title":"Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20089840","citation_count":63,"is_preprint":false},{"pmid":"11420239","id":"PMC_11420239","title":"Cloning and characterization of the cyclic guanosine monophosphate-inhibited phosphodiesterase PDE3A expressed in mouse oocyte.","date":"2001","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/11420239","citation_count":62,"is_preprint":false},{"pmid":"23651021","id":"PMC_23651021","title":"GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.","date":"2013","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/23651021","citation_count":59,"is_preprint":false},{"pmid":"11115397","id":"PMC_11115397","title":"Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11115397","citation_count":42,"is_preprint":false},{"pmid":"8695850","id":"PMC_8695850","title":"Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8695850","citation_count":40,"is_preprint":false},{"pmid":"34707099","id":"PMC_34707099","title":"Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34707099","citation_count":38,"is_preprint":false},{"pmid":"24248367","id":"PMC_24248367","title":"Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24248367","citation_count":33,"is_preprint":false},{"pmid":"22051884","id":"PMC_22051884","title":"Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility.","date":"2011","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22051884","citation_count":33,"is_preprint":false},{"pmid":"30603956","id":"PMC_30603956","title":"miRNA-27a-3p and miRNA-222-3p as Novel Modulators of Phosphodiesterase 3a (PDE3A) in Cerebral Microvascular Endothelial Cells.","date":"2019","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30603956","citation_count":31,"is_preprint":false},{"pmid":"31749907","id":"PMC_31749907","title":"Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.","date":"2019","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31749907","citation_count":25,"is_preprint":false},{"pmid":"8921398","id":"PMC_8921398","title":"Molecular cloning and chromosomal assignment of the human homologue of the rat cGMP-inhibited phosphodiesterase 1 (PDE3A)--a gene involved in fat metabolism located at 11p 15.1.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8921398","citation_count":25,"is_preprint":false},{"pmid":"35104454","id":"PMC_35104454","title":"Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death.","date":"2022","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35104454","citation_count":25,"is_preprint":false},{"pmid":"10828019","id":"PMC_10828019","title":"Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10828019","citation_count":25,"is_preprint":false},{"pmid":"31598394","id":"PMC_31598394","title":"PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.","date":"2019","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31598394","citation_count":25,"is_preprint":false},{"pmid":"27053290","id":"PMC_27053290","title":"A PDE3A mutation in familial hypertension and brachydactyly syndrome.","date":"2016","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27053290","citation_count":24,"is_preprint":false},{"pmid":"33234378","id":"PMC_33234378","title":"Di (2-ethylhexyl) phthalate impairs primordial follicle assembly by increasing PDE3A expression in oocytes.","date":"2020","source":"Environmental pollution (Barking, Essex : 1987)","url":"https://pubmed.ncbi.nlm.nih.gov/33234378","citation_count":24,"is_preprint":false},{"pmid":"31051182","id":"PMC_31051182","title":"Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload.","date":"2019","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/31051182","citation_count":23,"is_preprint":false},{"pmid":"30871701","id":"PMC_30871701","title":"A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium.","date":"2019","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30871701","citation_count":19,"is_preprint":false},{"pmid":"28678321","id":"PMC_28678321","title":"PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28678321","citation_count":16,"is_preprint":false},{"pmid":"32914566","id":"PMC_32914566","title":"Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells.","date":"2020","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/32914566","citation_count":16,"is_preprint":false},{"pmid":"9826434","id":"PMC_9826434","title":"Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.","date":"1998","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9826434","citation_count":16,"is_preprint":false},{"pmid":"10679291","id":"PMC_10679291","title":"Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: similarity and difference to adipocyte type PDE3B gene.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10679291","citation_count":15,"is_preprint":false},{"pmid":"9631239","id":"PMC_9631239","title":"Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure.","date":"1998","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9631239","citation_count":14,"is_preprint":false},{"pmid":"21099356","id":"PMC_21099356","title":"Female infertility in PDE3A(-/-) mice: polo-like kinase 1 (Plk1) may be a target of protein kinase A (PKA) and involved in meiotic arrest of oocytes from PDE3A(-/-) mice.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21099356","citation_count":14,"is_preprint":false},{"pmid":"37035914","id":"PMC_37035914","title":"Mutations in Phosphodiesterase 3A (PDE3A) Cause Hypertension Without Cardiac Damage.","date":"2023","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/37035914","citation_count":13,"is_preprint":false},{"pmid":"36936869","id":"PMC_36936869","title":"ETV1 inhibition depressed M2 polarization of tumor-associated macrophage and cell process in gastrointestinal stromal tumor via down-regulating PDE3A.","date":"2023","source":"Journal of clinical biochemistry and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/36936869","citation_count":12,"is_preprint":false},{"pmid":"30672071","id":"PMC_30672071","title":"Electroacupuncture promotes the gastrointestinal motility of diabetic mice by CNP/NPR-B-cGMP and PDE3A-cGMP signaling.","date":"2019","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/30672071","citation_count":12,"is_preprint":false},{"pmid":"26018892","id":"PMC_26018892","title":"Hypertension linked to PDE3A activation.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26018892","citation_count":12,"is_preprint":false},{"pmid":"30080287","id":"PMC_30080287","title":"Lack of microRNA-155 ameliorates renal fibrosis by targeting PDE3A/TGF-β1/Smad signaling in mice with obstructive nephropathy.","date":"2018","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/30080287","citation_count":12,"is_preprint":false},{"pmid":"31549136","id":"PMC_31549136","title":"Hypertension and Brachydactyly Syndrome Associated With Vertebral Artery Malformation Caused by a PDE3A Missense Mutation.","date":"2020","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/31549136","citation_count":10,"is_preprint":false},{"pmid":"31401933","id":"PMC_31401933","title":"High cGMP and low PDE3A activity are associated with oocyte meiotic incompetence.","date":"2019","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/31401933","citation_count":10,"is_preprint":false},{"pmid":"9631238","id":"PMC_9631238","title":"Cyclic nucleotide PDE-3. Quantitation of PDE-3A and -3B mRNAs in rat tissues by RNase protection assay.","date":"1998","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9631238","citation_count":10,"is_preprint":false},{"pmid":"28743736","id":"PMC_28743736","title":"SFPQ, a multifunctional nuclear protein, regulates the transcription of PDE3A.","date":"2017","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/28743736","citation_count":9,"is_preprint":false},{"pmid":"27975297","id":"PMC_27975297","title":"cUMP hydrolysis by PDE3A.","date":"2016","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27975297","citation_count":9,"is_preprint":false},{"pmid":"30209282","id":"PMC_30209282","title":"PDE3A gene screening improves diagnostics for patients with Bilginturan syndrome (hypertension and brachydactyly syndrome).","date":"2018","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/30209282","citation_count":9,"is_preprint":false},{"pmid":"39437010","id":"PMC_39437010","title":"First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39437010","citation_count":8,"is_preprint":false},{"pmid":"39406931","id":"PMC_39406931","title":"Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.","date":"2024","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/39406931","citation_count":7,"is_preprint":false},{"pmid":"33249558","id":"PMC_33249558","title":"Identification and functional study of genetic polymorphisms in cyclic nucleotide phosphodiesterase 3A (PDE3A).","date":"2020","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33249558","citation_count":7,"is_preprint":false},{"pmid":"26205238","id":"PMC_26205238","title":"Charting the interactome of PDE3A in human cells using an IBMX based chemical proteomics approach.","date":"2015","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/26205238","citation_count":7,"is_preprint":false},{"pmid":"29216268","id":"PMC_29216268","title":"Docking and quantitative structure-activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29216268","citation_count":7,"is_preprint":false},{"pmid":"39166256","id":"PMC_39166256","title":"Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression.","date":"2024","source":"Neuro-oncology advances","url":"https://pubmed.ncbi.nlm.nih.gov/39166256","citation_count":6,"is_preprint":false},{"pmid":"1314573","id":"PMC_1314573","title":"Insulin and isoproterenol induce phosphorylation of the particulate cyclic GMP-inhibited, low Km cyclic AMP phosphodiesterase (cGI PDE) in 3T3-L1 adipocytes.","date":"1992","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1314573","citation_count":6,"is_preprint":false},{"pmid":"38864850","id":"PMC_38864850","title":"A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/38864850","citation_count":6,"is_preprint":false},{"pmid":"25493569","id":"PMC_25493569","title":"PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis.","date":"2014","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/25493569","citation_count":6,"is_preprint":false},{"pmid":"39411532","id":"PMC_39411532","title":"Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12.","date":"2024","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/39411532","citation_count":5,"is_preprint":false},{"pmid":"27765510","id":"PMC_27765510","title":"Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity.","date":"2016","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27765510","citation_count":5,"is_preprint":false},{"pmid":"39435735","id":"PMC_39435735","title":"Pde3a and Pde3b regulation of murine pulmonary artery smooth muscle cell growth and metabolism.","date":"2024","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/39435735","citation_count":5,"is_preprint":false},{"pmid":"31589936","id":"PMC_31589936","title":"PDE3A variant associated with hypertension and brachydactyly syndrome in a patient with ischemic stroke caused by spontaneous intracranial artery dissection: A review of the clinical and molecular genetic features.","date":"2019","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31589936","citation_count":4,"is_preprint":false},{"pmid":"36979891","id":"PMC_36979891","title":"PDE3A and GSK3B as Atrial Fibrillation Susceptibility Genes in the Chinese Population via Bioinformatics and Genome-Wide Association Analysis.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36979891","citation_count":4,"is_preprint":false},{"pmid":"38244313","id":"PMC_38244313","title":"ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate cancer metastasis and M2 polarization in lung cancer with EGFR mutations.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38244313","citation_count":4,"is_preprint":false},{"pmid":"38001568","id":"PMC_38001568","title":"PDE3A Is a Highly Expressed Therapy Target in Myxoid Liposarcoma.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38001568","citation_count":4,"is_preprint":false},{"pmid":"28838830","id":"PMC_28838830","title":"Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation.","date":"2017","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28838830","citation_count":4,"is_preprint":false},{"pmid":"37296663","id":"PMC_37296663","title":"CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37296663","citation_count":3,"is_preprint":false},{"pmid":"32631253","id":"PMC_32631253","title":"Whole-exome sequencing identifies a de novo PDE3A variant causing autosomal dominant hypertension with brachydactyly type E syndrome: a case report.","date":"2020","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32631253","citation_count":2,"is_preprint":false},{"pmid":"40563987","id":"PMC_40563987","title":"IGF2BP3 Modulates mRNA Splicing and Stability to Promote Trophoblast Progression via Interaction with PDE3A and Suppression by miR-196a-5p in Preeclampsia.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40563987","citation_count":1,"is_preprint":false},{"pmid":"40497949","id":"PMC_40497949","title":"PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/40497949","citation_count":1,"is_preprint":false},{"pmid":"41726589","id":"PMC_41726589","title":"The Role of PDE3A in Cancer.","date":"2026","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/41726589","citation_count":0,"is_preprint":false},{"pmid":"41673703","id":"PMC_41673703","title":"AR-mediated YBX3 suppresses oocyte meiotic resumption in polycystic ovary syndrome by attenuating Pde3A and Ccnb1 expression.","date":"2026","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/41673703","citation_count":0,"is_preprint":false},{"pmid":"38845116","id":"PMC_38845116","title":"RETRACTION: Lack of MicroRNA-155 Ameliorates Renal Fibrosis by Targeting PDE3A/TGF-β1/Smad Signaling in Mice with Obstructive Nephropathy.","date":"2024","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/38845116","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.10.648087","title":"Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitors","date":"2025-04-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.10.648087","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.24.645113","title":"β-aminopropionitrile-induced thoracic aortopathy is refractory to cilostazol and sildenafil in mice","date":"2025-03-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.24.645113","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.27.24309406","title":"Transcriptome- and proteome-wide Mendelian randomization to prioritize therapeutic targets for coronary heart disease","date":"2024-06-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.27.24309406","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38838,"output_tokens":6466,"usd":0.106752},"stage2":{"model":"claude-opus-4-6","input_tokens":10091,"output_tokens":4101,"usd":0.22947},"total_usd":0.336222,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Three PDE3A isoforms (PDE3A-136, PDE3A-118, PDE3A-94) exist in cardiac myocytes, translated from two mRNAs derived from the PDE3A1 gene; they differ in N-terminal sequences containing membrane-association domains and phosphorylation/activation sites for PKA and PKB, determining their distinct subcellular localizations.\",\n      \"method\": \"Western blotting with isoform-specific antibodies, in vitro transcription/translation, RT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, replicated within a single rigorous study\",\n      \"pmids\": [\"12154085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PKB/Akt phosphorylates PDE3A at serines 290-292 in mouse oocytes, increasing cAMP-hydrolytic activity and promoting meiotic maturation; mutation of these serines to alanine greatly diminishes insulin-dependent maturation in Xenopus and mouse oocytes.\",\n      \"method\": \"Cell-free kinase assay with recombinant PDE3A and PKB/Akt, site-directed mutagenesis, microinjection of myr-Akt into oocytes, pde3a(-/-) rescue experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro phosphorylation, mutagenesis, and functional rescue in two model organisms\",\n      \"pmids\": [\"17124499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phosphorylation of human PDE3A1 by PKA at Ser-292/Ser-293 (unique to PDE3A1 N-terminal extension) promotes incorporation of PDE3A1 into a SERCA2/AKAP18 signalosome in the sarcoplasmic reticulum, where it regulates PLB phosphorylation and SERCA2 activity controlling cardiac contractility.\",\n      \"method\": \"Co-immunoprecipitation, gel filtration chromatography, recombinant protein phosphorylation assay, N-terminal deletion mutants, Ser-to-Ala substitution mutagenesis, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis, reconstitution with recombinant proteins, and co-IP in human SR fractions\",\n      \"pmids\": [\"25593322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Gain-of-function missense mutations in PDE3A increase PKA-mediated phosphorylation of PDE3A, resulting in increased cAMP-hydrolytic activity, enhanced VSMC and chondrocyte proliferation, diminished phospho-VASP levels, and dysregulated PTHrP, causing autosomal dominant hypertension with brachydactyly.\",\n      \"method\": \"In vitro cAMP hydrolysis assays on MSC-derived VSMCs and chondrocytes, analysis of phosphorylation state, VASP and PTHrP measurements\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional in vitro assays on disease-relevant cells with multiple molecular readouts\",\n      \"pmids\": [\"25961942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DNMDP binding to PDE3A promotes a neomorphic protein-protein interaction between PDE3A and Schlafen 12 (SLFN12), and coexpression of both proteins is required for DNMDP-induced cancer cell death; PDE3A depletion confers DNMDP resistance.\",\n      \"method\": \"Phenotypic compound library screening across 766 cancer cell lines, target deconvolution by predictive chemogenomics, co-immunoprecipitation, siRNA knockdown\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, genetic depletion with defined phenotypic readout, large-scale correlative validation\",\n      \"pmids\": [\"26656089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PDE3A and SLFN12 form a heterotetramer stabilized by DNMDP; interactions between the C-terminal alpha helix of SLFN12 and residues near the PDE3A active site are required for complex formation; PDE3A binding increases SLFN12 RNase activity, and SLFN12 RNase activity is required for DNMDP-induced cell death.\",\n      \"method\": \"Crystal/cryo-EM structure of PDE3A-SLFN12 complex, mutagenesis of interface residues, in vitro RNase activity assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural determination with mutagenesis and functional validation of enzymatic activity\",\n      \"pmids\": [\"34272366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structures of PDE3A-SLFN12 heterotetramer bound to anagrelide, nauclefine, or DNMDP reveal that molecular glue compounds bind the PDE3A catalytic domain pocket and create a modified interface that recruits the SLFN12 short helix (E552-I558) via hydrophobic interactions; SLFN12 activation blocks protein translation leading to apoptosis.\",\n      \"method\": \"High-resolution cryo-EM of complexes isolated from drug-treated HeLa cells, structure-based analog design\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — independent cryo-EM structure corroborating and extending the companion structural study\",\n      \"pmids\": [\"34707099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Platelet agonists (e.g., thrombin via PAR-1) activate PKC to phosphorylate PDE3A on Ser-312, Ser-428, Ser-438, Ser-465, and Ser-492, increasing cAMP hydrolysis and promoting association of PDE3A with 14-3-3 proteins; PKC activation, but not PI3K/PKB, mTOR/p70S6K, or ERK/RSK, is required for this phosphorylation.\",\n      \"method\": \"Mass spectrometry phosphosite identification, pharmacological inhibition of kinase pathways, co-immunoprecipitation with 14-3-3\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified phosphosites combined with selective kinase inhibitors and reciprocal co-IP\",\n      \"pmids\": [\"19261611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In gastric smooth muscle, PKA phosphorylates PDE3A (not PDE3B) and activates its cAMP-hydrolytic activity; cGMP inhibits PDE3 activity and augments cAMP levels; PKG does not regulate PDE3A phosphorylation.\",\n      \"method\": \"RT-PCR/Western blot for isoform identification, PKA/PKG-selective pharmacological tools (PKI, H-89, KT-5823), PDE activity assays, phosphorylation assays\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple selective inhibitors used orthogonally with enzymatic activity assays\",\n      \"pmids\": [\"11832336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE3A deletion in VSMCs suppresses mitogen-induced proliferation via two complementary pathways: (1) elevated PKA activity causes inhibitory phosphorylation of Raf-1 (Ser-259), reducing ERK activation; (2) PKA/CREB-mediated induction of p21 and p53 accumulation elevates MKP-1 and causes G0/G1 cell cycle arrest.\",\n      \"method\": \"PDE3A knockout mouse VSMCs, adenoviral CREB overexpression, siRNA knockdown of p53, ERK/Raf-1 phosphorylation assays, cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple pathway readouts, genetic rescue experiments\",\n      \"pmids\": [\"21632535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PDE3A1 and PDE3A2 isoforms are phosphorylated at different sites by distinct kinases in cardiac myocytes: isoproterenol/PKA selectively phosphorylates PDE3A1 at S312 (14-3-3 binding site), while PMA/PKC selectively phosphorylates PDE3A2 at S428; phosphorylation at S428 stimulates PDE3A2 activity but S312 phosphorylation does not affect PDE3A1 activity; the two isoforms have distinct protein interactomes.\",\n      \"method\": \"FLAG-tagged isoform expression in HEK293 cells, phospho-specific detection, gel filtration chromatography, 2D electrophoresis of co-immunoprecipitated proteins, human myocardium validation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, validated in human myocardium\",\n      \"pmids\": [\"24248367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PDE3A physically and functionally interacts with CFTR at the plasma membrane; PDE3A inhibition generates compartmentalized cAMP that further clusters PDE3A and CFTR into microdomains; actin cytoskeleton disruption reduces PDE3A-CFTR interaction and abolishes compartmentalized cAMP signaling and CFTR channel potentiation.\",\n      \"method\": \"Co-immunoprecipitation, pharmacological PDE3A inhibition, actin disruption, CFTR channel electrophysiology, gland secretion assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, functional channel assay, physiological tissue model\",\n      \"pmids\": [\"20089840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Conserved histidine and glutamate residues in the two HXXXH(X)25E metal-binding motifs of PDE3A are critical for catalysis and substrate/inhibitor binding: H752, H756, E825 mutations abolish or greatly reduce catalytic activity; H836A increases Ki for cGMP 177-fold; E866A increases Km for cAMP 11-fold and Ki for cGMP 27-fold; E971A increases Km 5-fold.\",\n      \"method\": \"Site-directed mutagenesis, expression in baculovirus/Sf9 system, kinetic analysis (kcat, Km, Ki)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic analysis of multiple active-site mutants with rigorous controls\",\n      \"pmids\": [\"10828019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Site-directed mutagenesis of platelet PDE3A identified H840 as essential for catalysis (likely coordinates Mn2+) and H869 as important for cGMP inhibitor binding (H869A increases Km for cAMP and IC50 for cGMP fourfold each); C816 in the 44-aa PDE3-unique insert is essential for proper folding.\",\n      \"method\": \"Site-directed mutagenesis, expression in PDE-deficient yeast Saccharomyces cerevisiae, kinetic analysis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic characterization of multiple mutants\",\n      \"pmids\": [\"9826434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The PDE3A catalytic domain is localized to amino acid residues 679-1141; deletion constructs PDE3Adelta1 (aa 665-1141) and PDE3Adelta2 (aa 679-1141) retain catalytic activity, while PDE3Adelta3 (aa 686-1141) and PDE3Adelta4 (aa 700-1141) do not.\",\n      \"method\": \"Deletion mutagenesis, expression in PDE-deficient yeast, PDE activity assays, Western blotting\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic deletion analysis with activity measurements\",\n      \"pmids\": [\"8695850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Mouse oocyte PDE3A is recovered predominantly in the soluble fraction when N-terminally truncated (Delta346aa or Delta608aa), whereas full-length recombinant PDE3A is in the particulate fraction; the N-terminal region contains the membrane-association determinants.\",\n      \"method\": \"Subcellular fractionation of Leydig cell-expressed truncation mutants, pharmacological profiling vs. oocyte PDE activity\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation of defined deletion mutants, correlated with functional inhibitor profiling\",\n      \"pmids\": [\"11420239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A vascular smooth muscle cell PDE3A isoform (PDE3A2/~118 kDa) is generated from the same gene as cardiac PDE3A1 via a pre-translational mechanism that removes the first 145 N-terminal amino acids of PDE3A1, including one membrane-association domain.\",\n      \"method\": \"cDNA cloning from aortic myocytes, 5'-RACE, RT-PCR, ribonuclease protection assay, Western blotting with region-specific antibodies, Sf9 expression\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple molecular biology methods converging on same conclusion\",\n      \"pmids\": [\"11115397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In PDE3A(-/-) oocytes, elevated PKA activity inactivates both Cdc2 and Plk1, inhibits histone H3-S10 phosphorylation and Cdc25B dephosphorylation, causing G2/M arrest; PKAc fails to translocate to the nucleus; Plk1 is reactivated by PKA inhibitor; PDE3A co-immunoprecipitates with Plk1 and PKAc can phosphorylate and inhibit Plk1 in vitro.\",\n      \"method\": \"PDE3A knockout mouse oocytes, in vitro PKA phosphorylation of recombinant Plk1, co-immunoprecipitation, PKA inhibitor (Rp-cAMPS) rescue, subcellular localization imaging\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO, in vitro kinase assay, co-IP, and pharmacological rescue\",\n      \"pmids\": [\"21099356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In rat tissues and VSMCs, PDE3A is expressed as a ~120 kDa protein found exclusively in the cytosolic fraction, whereas PDE3B (~135 kDa) is found only in the particulate fraction; prolonged elevation of cAMP increases PDE3A and PDE3B expression and shifts PDE3 activity to particulate fractions.\",\n      \"method\": \"Subcellular fractionation, immunoblotting with isoform-selective antisera, RT-PCR, cAMP-elevating agent treatment\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation with isoform-specific detection across multiple tissues\",\n      \"pmids\": [\"9884079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Chemical proteomics using an IBMX-based affinity resin in HeLa cells identified the PDE3A interactome, including 14-3-3 proteins and a PP2A complex (regulatory, scaffold, and catalytic subunits) as endogenous PDE3A-associated proteins.\",\n      \"method\": \"Chemical proteomics (IBMX-affinity resin + selective competitor PDE inhibitors), mass spectrometry identification of co-purified proteins\",\n      \"journal\": \"Molecular bioSystems\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS-based interactome with competitive specificity controls, single lab\",\n      \"pmids\": [\"26205238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PDE3A hydrolyzes cUMP with low affinity (Km ~143 μM) and high velocity (Vmax ~42 μmol/min/mg), compared to cAMP (Km ~0.7 μM, Vmax ~1.2 μmol/min/mg); the PDE3 inhibitor milrinone inhibits cUMP hydrolysis by PDE3A with Ki = 57 nM.\",\n      \"method\": \"In vitro enzyme kinetics with HPLC-MS/MS detection of UMP and AMP products, milrinone inhibition assay\",\n      \"journal\": \"Naunyn-Schmiedeberg's archives of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetic characterization, single study\",\n      \"pmids\": [\"27975297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cytotoxic PDE3A modulators act as molecular glues inducing PDE3A-SLFN12 association; the PDE3A-SLFN12 interaction stabilizes cytoplasmic SLFN12 and induces SLFN12 dephosphorylation at Ser-368 and Ser-573; this dephosphorylation is required for cell death and promotes rRNA RNase activity of SLFN12.\",\n      \"method\": \"Co-immunoprecipitation, mutational analysis of SLFN12 phosphosites, RNase activity assay, cell viability with phospho-mimetic/alanine mutants\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus mutagenesis of phosphosites with functional cell-death readout, multiple orthogonal methods\",\n      \"pmids\": [\"35104454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ATF3 transcription factor binds a 29-nt insertion polymorphism in the PDE3A promoter and represses cAMP-dependent PDE3A1 transcription; a nearby cAMP response element enhancer is blocked by the insertion, explaining differential PDE3A1 expression in response to PDE3 inhibitor treatment in heart failure patients.\",\n      \"method\": \"Luciferase reporter assay, mRNA RT-PCR in explanted human LV, PDE enzyme activity assay, promoter deletion analysis\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional promoter assay and human tissue validation, single lab\",\n      \"pmids\": [\"30871701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SFPQ (splicing factor proline and glutamine rich) binds upstream regulatory regions of PDE3A and activates its transcription; serum-induced PDE3A expression is dependent on SFPQ binding; PDE3A transcription initiates from multiple start sites within exon 1.\",\n      \"method\": \"5'-RACE for transcription start site mapping, ChIP-seq for SFPQ binding sites, SFPQ overexpression and knockdown effects on PDE3A mRNA\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq plus functional expression analysis, single lab\",\n      \"pmids\": [\"28743736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In human pulmonary artery smooth muscle cells, nitric oxide increases PDE3A protein expression and PDE3 activity via the sGC-cGMP pathway, leading to decreased cAMP and increased AMPK phosphorylation; siRNA knockdown of PDE3A blunts NO-induced AMPK activation.\",\n      \"method\": \"siRNA knockdown, Western blotting, cAMP assay, pharmacological sGC stimulator/inhibitor\",\n      \"journal\": \"Physiological reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown with specific mechanistic pathway readout, single lab\",\n      \"pmids\": [\"32914566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-27a-3p and miR-222-3p directly reduce PDE3A protein expression in human cerebral microvascular endothelial cells (hCMEC/D3) when transfected as mimics.\",\n      \"method\": \"miRNA mimic transfection, Western blotting\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single method (Western blot after miRNA transfection), single lab, no functional consequence established\",\n      \"pmids\": [\"30603956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The cGMP-inhibited PDE (PDE3A) in 3T3-L1 adipocyte particulate fractions is phosphorylated in response to beta-agonist or insulin in intact cells, indicating hormonal regulation of PDE3A phosphorylation state.\",\n      \"method\": \"32P metabolic labeling, immunoprecipitation with anti-cGI PDE antibody\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in-cell phosphorylation assay with two distinct hormonal stimuli, foundational early study\",\n      \"pmids\": [\"1314573\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PDE3A is a cAMP/cGMP-hydrolyzing phosphodiesterase whose activity is regulated by PKA, PKC, and PKB/Akt-mediated phosphorylation at distinct isoform-specific sites; in the heart, PKA phosphorylation of PDE3A1 at Ser-292/293 drives its assembly into SERCA2/AKAP18 signalosomes that control contractility, while in oocytes PKB/Akt phosphorylation at Ser-290-292 activates PDE3A to lower cAMP and trigger meiotic resumption; in platelets and VSMCs, PKC phosphorylation activates PDE3A and promotes 14-3-3 binding, suppressing cAMP signaling; gain-of-function mutations in PDE3A hyperactivate the enzyme causing familial hypertension with brachydactyly; and independently of its enzymatic function, certain small-molecule 'velcrin' modulators induce PDE3A to form a heterotetramer with SLFN12, activating SLFN12's tRNase activity and inducing cancer cell apoptosis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PDE3A is a dual-specificity cyclic nucleotide phosphodiesterase that hydrolyzes cAMP and cGMP, with cGMP also acting as a competitive inhibitor, and serves as a critical regulator of cAMP compartmentalization in cardiovascular, reproductive, and hematopoietic cells [PMID:10828019, PMID:8695850]. Three N-terminal isoforms (PDE3A1/136 kDa, PDE3A2/118 kDa, PDE3A3/94 kDa), generated by alternative translation initiation from a single gene, differ in membrane-association domains and phosphorylation sites, conferring distinct subcellular localizations and signalosome partnerships: PKA phosphorylation of PDE3A1 at Ser-292/293 drives its assembly into a SERCA2/AKAP18 complex at the sarcoplasmic reticulum to control cardiac contractility, PKB/Akt phosphorylation at Ser-290–292 activates PDE3A in oocytes to lower cAMP and permit meiotic resumption, and PKC phosphorylation in platelets promotes 14-3-3 binding and cAMP suppression [PMID:12154085, PMID:25593322, PMID:17124499, PMID:19261611]. In vascular smooth muscle cells, PDE3A deletion elevates PKA activity, which inhibits Raf-1/ERK signaling and induces p21/p53-dependent G0/G1 arrest, suppressing proliferation [PMID:21632535]. Gain-of-function PDE3A mutations cause autosomal dominant hypertension with brachydactyly type E, and independently of catalytic activity, small-molecule molecular glues induce PDE3A to form a heterotetramer with SLFN12, activating SLFN12 RNase/translational shutdown and triggering cancer cell apoptosis [PMID:25961942, PMID:34272366, PMID:34707099].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing that PDE3A is hormonally regulated by phosphorylation set the stage for understanding how catecholamines and insulin tune cAMP hydrolysis in intact cells.\",\n      \"evidence\": \"32P metabolic labeling and immunoprecipitation in 3T3-L1 adipocytes after beta-agonist or insulin stimulation\",\n      \"pmids\": [\"1314573\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase identity not determined\", \"Phosphorylation sites not mapped\", \"Functional consequence on PDE activity not directly measured\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defining the catalytic domain boundaries (residues 679–1141) and identifying essential metal-coordinating histidine/glutamate residues resolved how PDE3A achieves dual cAMP/cGMP hydrolysis and how cGMP acts as a competitive inhibitor.\",\n      \"evidence\": \"Systematic deletion mutagenesis in PDE-deficient yeast and site-directed mutagenesis with kinetic analysis of recombinant enzyme\",\n      \"pmids\": [\"8695850\", \"9826434\", \"10828019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of PDE3A catalytic domain alone at this stage\", \"Precise mechanism of cGMP competitive inhibition at atomic resolution unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that the PDE3A N-terminal region encodes membrane-association determinants and that alternative pre-translational mechanisms generate tissue-specific isoforms (PDE3A1 vs PDE3A2) explained how a single gene produces proteins with distinct subcellular distributions in heart versus vasculature.\",\n      \"evidence\": \"Subcellular fractionation of N-terminal truncation mutants, 5'-RACE, and isoform-specific antibodies across rat tissues and VSMCs\",\n      \"pmids\": [\"11420239\", \"11115397\", \"9884079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of alternative translation initiation not fully characterized\", \"Functional non-redundancy of isoforms not yet demonstrated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of three cardiac PDE3A isoforms (PDE3A1/136, PDE3A2/118, PDE3A3/94 kDa) from two mRNAs, each with unique N-terminal PKA/PKB sites, established the molecular basis for isoform-specific regulation in the heart.\",\n      \"evidence\": \"Isoform-specific antibodies, in vitro transcription/translation, RT-PCR in cardiac myocytes\",\n      \"pmids\": [\"12154085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo functional distinction between isoforms in intact heart not yet shown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that PKB/Akt phosphorylates PDE3A at Ser-290–292 to activate cAMP hydrolysis and trigger meiotic resumption revealed PDE3A as the critical effector downstream of insulin/PI3K signaling in oocyte maturation.\",\n      \"evidence\": \"Cell-free kinase assay, Ser-to-Ala mutagenesis, microinjection of myr-Akt, pde3a−/− oocyte rescue in Xenopus and mouse\",\n      \"pmids\": [\"17124499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional kinases co-regulate PDE3A in oocytes not excluded\", \"Structural basis of phosphorylation-induced activation unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping five PKC-dependent phosphorylation sites (Ser-312, -428, -438, -465, -492) on platelet PDE3A and showing that these drive 14-3-3 binding revealed a distinct kinase-specific regulatory module controlling cAMP in hemostasis.\",\n      \"evidence\": \"Mass spectrometry phosphosite identification, selective kinase inhibitors, co-IP with 14-3-3 in thrombin-stimulated platelets\",\n      \"pmids\": [\"19261611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of individual phosphosites on platelet aggregation not dissected\", \"Identity of specific 14-3-3 isoforms involved not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showing that PDE3A−/− oocytes arrest at G2/M because elevated PKA inactivates Plk1 and Cdc2, and that PDE3A co-immunoprecipitates with Plk1, positioned PDE3A within the meiotic cell-cycle kinase cascade.\",\n      \"evidence\": \"PDE3A knockout mouse oocytes, in vitro PKA phosphorylation of Plk1, co-IP, PKA inhibitor rescue\",\n      \"pmids\": [\"21099356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PKA phosphosite on Plk1 that mediates inhibition not mapped in vivo\", \"Whether PDE3A-Plk1 interaction is direct or scaffold-mediated unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstration that PDE3A interacts with CFTR at the plasma membrane and that actin cytoskeleton integrity is required for this compartmentalized cAMP signaling revealed PDE3A as a regulator of chloride channel function.\",\n      \"evidence\": \"Reciprocal co-IP, CFTR electrophysiology, actin disruption in airway epithelial cells\",\n      \"pmids\": [\"20089840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PDE3A directly binds CFTR or via an adaptor not resolved\", \"Physiological impact on mucociliary clearance not tested in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"PDE3A deletion in VSMCs established that PDE3A sustains proliferative signaling through two parallel cAMP-PKA-suppressive arms: enabling Raf-1/ERK activation and preventing p21/p53-mediated G0/G1 arrest.\",\n      \"evidence\": \"PDE3A knockout mouse VSMCs, adenoviral CREB overexpression, p53 siRNA rescue, ERK/Raf-1 phosphorylation assays\",\n      \"pmids\": [\"21632535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of PDE3A versus PDE3B to in vivo vascular remodeling not separated\", \"Relevance to human atherosclerotic VSMCs not confirmed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealing that PKA selectively phosphorylates PDE3A1 at Ser-312 (promoting 14-3-3 binding without increasing activity) while PKC selectively phosphorylates PDE3A2 at Ser-428 (stimulating activity) demonstrated isoform-specific regulatory logic within the same cell type.\",\n      \"evidence\": \"FLAG-tagged isoform expression in HEK293, phospho-specific detection, gel filtration, validated in human myocardium\",\n      \"pmids\": [\"24248367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct interactomes of PDE3A1 vs PDE3A2 identified by 2D-gel but individual partners not validated\", \"Functional cardiac phenotype of isoform-selective disruption not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PKA phosphorylation of PDE3A1 at Ser-292/293 was shown to drive its incorporation into a SERCA2/AKAP18 signalosome at the sarcoplasmic reticulum, directly linking PDE3A1 to regulation of PLB phosphorylation and cardiac contractility.\",\n      \"evidence\": \"Co-IP, gel filtration, Ser-to-Ala mutagenesis, recombinant protein reconstitution in human SR fractions\",\n      \"pmids\": [\"25593322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo cardiac functional consequence of disrupting PDE3A1-AKAP18 interaction not demonstrated\", \"Stoichiometry of the signalosome not determined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of gain-of-function PDE3A mutations as the cause of autosomal dominant hypertension with brachydactyly type E established PDE3A as a disease gene and connected enhanced cAMP hydrolysis to vascular and skeletal pathology.\",\n      \"evidence\": \"In vitro cAMP hydrolysis assays on MSC-derived VSMCs/chondrocytes from mutation carriers, phospho-VASP and PTHrP measurements\",\n      \"pmids\": [\"25961942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural mechanism by which mutations enhance phosphorylation-dependent activation not resolved\", \"Contribution of vascular versus skeletal phenotype to hypertension not dissected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that small-molecule DNMDP induces a neomorphic PDE3A–SLFN12 protein-protein interaction essential for selective cancer cell killing opened a catalysis-independent, molecular-glue function for PDE3A.\",\n      \"evidence\": \"Chemogenomic screening across 766 cancer cell lines, co-IP, siRNA resistance studies\",\n      \"pmids\": [\"26656089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of cell death downstream of PDE3A-SLFN12 complex not yet defined\", \"Structural basis of glue-induced interaction unknown at this point\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cryo-EM and crystal structures of the PDE3A–SLFN12 heterotetramer revealed that molecular glues bind the PDE3A catalytic pocket and create a hydrophobic interface that recruits a SLFN12 C-terminal helix, activating SLFN12 RNase activity to block translation and induce apoptosis.\",\n      \"evidence\": \"Cryo-EM structures with DNMDP/anagrelide/nauclefine, mutagenesis of interface residues, in vitro RNase assay\",\n      \"pmids\": [\"34272366\", \"34707099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo tRNA substrate specificity of activated SLFN12 not fully characterized\", \"Determinants of cancer-cell selectivity beyond PDE3A-SLFN12 coexpression not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing that PDE3A-SLFN12 complex formation triggers SLFN12 dephosphorylation at Ser-368/Ser-573 and that this dephosphorylation is required for rRNA cleavage and cell death added a phosphorylation-dependent gating step to the molecular-glue killing mechanism.\",\n      \"evidence\": \"Co-IP, phosphosite-mimetic/alanine mutagenesis of SLFN12, RNase activity assay, cell viability readouts\",\n      \"pmids\": [\"35104454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase responsible for SLFN12 dephosphorylation not identified\", \"Whether other Schlafen family members can substitute for SLFN12 not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: the structural basis of phosphorylation-induced PDE3A activation, the atomic-resolution structure of PDE3A catalytic domain alone, the in vivo cardiac phenotype of isoform-selective PDE3A disruption, the phosphatase acting on SLFN12 in the molecular-glue pathway, and the determinants beyond coexpression that confer cancer-cell selectivity to velcrin compounds.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of PDE3A catalytic domain alone\", \"In vivo isoform-selective genetic models lacking\", \"Phosphatase for SLFN12 dephosphorylation unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [12, 13, 14, 20]},\n      {\"term_id\": \"GO:0009975\", \"supporting_discovery_ids\": [12, 13, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15, 18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [11, 15, 18]},\n      {\"term_id\": \"GO:0043226\", \"supporting_discovery_ids\": [2, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 7, 8, 9, 11]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 9, 17]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 5, 6, 21]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [1, 17]}\n    ],\n    \"complexes\": [\n      \"SERCA2/AKAP18/PDE3A1 signalosome\",\n      \"PDE3A-SLFN12 heterotetramer\"\n    ],\n    \"partners\": [\n      \"SLFN12\",\n      \"AKAP18\",\n      \"ATP2A2\",\n      \"PLN\",\n      \"CFTR\",\n      \"YWHAZ\",\n      \"PLK1\",\n      \"PPP2CA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}